Recent developments include quarterly financial results showing ongoing losses with some revenue, clinical progress and data releases for SER-155, management changes, and regulatory interactions.

• Seres Therapeutics reported a Q3 2026 net loss of $16.3 million and revenue of $593,000, with cash and cash equivalents of $17.5 million as of September 30, 2026 [N1][S2].
• The company swung to a Q2 2026 profit supported by SER-155 clinical data in inflammatory refractory epithelial colitis (IrEC) [N2].
• SER-155 showed an 80% response rate in a cancer immunotherapy gastrointestinal toxicity study reported in July 2026 [N3].
• Seres received constructive feedback from the FDA on the Phase 2 study protocol for SER-155 and implemented workforce reductions in 2025 [N5].
• Management changes in 2025 included the resignation of CEO Eric Shaff and appointment of two co-CEOs [N5].
• The company is actively seeking partnerships to support clinical advancement and commercialization of SER-155 and other pipeline candidates [S1].

The company’s clinical data for SER-155, including an 80% response rate in a cancer immunotherapy GI toxicity study and positive Q2 2026 profitability supported by SER-155 data, demonstrate potential clinical value. Constructive FDA feedback on the Phase 2 study protocol and ongoing strategic discussions for partnerships may facilitate advancement of SER-155 and other pipeline candidates. If Seres can secure additional funding or collaborations, it may progress its clinical programs and build commercial capabilities leveraging its live biotherapeutics platform.

Seres faces substantial doubt about its ability to continue as a going concern beyond Q3 2026 due to ongoing losses and capital needs. The company’s limited operating history, reliance on a single lead candidate, and absence of commercial products beyond the sold VOWST asset increase execution risk. Failure to obtain timely funding or partnerships could force program delays, cost reductions, or operational wind-down. Regulatory, clinical, and market uncertainties inherent in biotherapeutics development add to the risk profile.

Seres Therapeutics’ moat is based on its proprietary live biotherapeutics platform and intellectual property portfolio, which underpin its pipeline of cultivated live biotherapeutic candidates. The company’s focus on SER-155 for reducing bloodstream infections in vulnerable patient populations addresses a significant unmet medical need. However, as a clinical-stage company with limited commercial products and significant financial constraints, its competitive advantage depends heavily on successful clinical development, regulatory approvals, and securing partnerships or funding to advance its pipeline and commercialization capabilities.

• Going Concern and Capital Risk: The company has identified substantial doubt about its ability to continue as a going concern beyond Q3 2026 due to ongoing losses and the need for additional funding or partnerships [S1].
• Clinical and Regulatory Risk: Advancement of SER-155 and other pipeline candidates depends on successful clinical trials and regulatory approvals, which are inherently uncertain [S1].
• Financial and Operational Risk: Seres has incurred significant losses historically and expects expenses to increase with clinical development and commercialization efforts. Failure to secure funding could lead to program delays or operational downsizing [S1].
• Market and Competitive Risk: The live biotherapeutics field is competitive and evolving, with technological and market developments that could impact Seres’ ability to commercialize products [S1].
• Management and Execution Risk: Recent management changes and workforce reductions may affect operational continuity and execution of strategic plans [N5][S1].

• Seres Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutic products.
• The company’s lead product candidate is SER-155, targeting reduction of bloodstream infections in medically vulnerable populations including allogeneic hematopoietic stem cell transplant (allo-HSCT) patients.
• Seres has completed a Phase 1b study of SER-155 in allo-HSCT patients and is planning a Phase 2 study.
• The company also has earlier-stage pipeline candidates such as SER-603 for inflammatory bowel disease (IBD) and other cultivated live biotherapeutic candidates.
• Seres sold its only FDA-approved product, VOWST, to Seres Pharmaceuticals Network (SPN) in September 2024 and now focuses on SER-155 and other pipeline assets.
• Financial snapshot as of September 30, 2026, shows cash and cash equivalents of $17.5 million, current assets of $34.4 million, current liabilities of $20.9 million, a current ratio of 1.65, and a cash ratio of 0.84.
• For Q3 2026, Seres reported revenue of $593,000 and a net loss of $16.3 million, with basic and diluted EPS of -$1.63 per share.
• The company has identified substantial doubt about its ability to continue as a going concern beyond the third quarter of 2026 due to capital needs and ongoing losses.
• Seres is actively seeking additional funding or partnerships to support clinical development and commercialization efforts, particularly for SER-155.
• The company’s expenses are expected to increase with ongoing clinical trials, manufacturing scale-up, regulatory activities, and potential commercialization.
• Recent news highlights include Q3 2026 loss with revenue above prior periods, Q2 2026 profitability swing supported by SER-155 data, and an 80% response rate reported in a cancer immunotherapy GI toxicity study for SER-155.
• Management changes occurred in mid-2025 with CEO Eric Shaff resigning and two co-CEOs appointed.
• The company received constructive FDA feedback on the Phase 2 study protocol for SER-155 and implemented workforce reductions in 2025.
• Seres’ business model centers on developing and commercializing live biotherapeutic products through clinical development, regulatory approval, and potential partnerships.
• The company’s financial condition and operating results have fluctuated significantly historically and are expected to continue doing so.
• The company’s ability to raise capital on acceptable terms is uncertain and critical to ongoing operations and development programs.